Table 1 Relationship between sorafenib resistance and intratumoral RCN1 expression, clinicopathologic features (n = 42).

From: RCN1 induces sorafenib resistance and malignancy in hepatocellular carcinoma by activating c-MYC signaling via the IRE1α–XBP1s pathway

No. (%) of patients

Characteristics

Total

Sorafenib-sensitive

Sorafenib-resistant

χ2

p-value

RCN1 expression

   

8.849

0.003a

 Low

24

20 (74.1)

4 (26.8)

–

–

 High

18

7 (25.9)

11 (73.2)

–

–

Age (y)

   

0.616

0.433

 <50

11

6 (22.2)

5 (33.3)

–

–

 ≥50

31

21 (77.8)

10 (66.7)

–

–

Gender

   

2.696

0.101

 Male

29

21 (77.8)

8 (53.3)

–

–

 Female

13

6 (22.2)

7 (46.7)

–

–

Cirrhosis

   

0.305

0.580

 Present

22

15 (55.6)

7 (46.6)

–

–

 Absent

20

12 (44.4)

8 (53.4)

–

–

HBV infection

   

0.017

0.895

 Positive

36

23 (85.2)

13 (86.7)

–

–

 Negative

6

4 (14.8)

2 (13.3)

–

–

Tumor size (cm)

   

10.996

0.001a

 <5

20

18 (66.7)

2 (13.3)

–

–

 ≥5

22

9 (33.3)

13 (86.7)

–

–

Vascular invasion

   

7.135

0.008a

 Presence

25

12 (44.4)

13 (86.7)

–

–

 Absence

17

15 (55.6)

2 (13.3)

–

–

AFP (ng/ml)

   

0.494

0.482

 ≤20

23

15 (55.6)

8 (53.4)

–

–

 >20

19

12 (44.4)

7 (46.6)

–

–

TNM stage

   

6.067

0.014a

 I

16

14 (51.9)

2 (13.3)

–

–

 II + III

26

13 (48.1)

13 (86.7)

–

–

  1. ap-value < 0.05.
Back to article page